Reflection Asset Management Invests $1.35 Million in Stryker Corporation $SYK

Posted by Brian Himes on Jun 20th, 2026

Reflection Asset Management bought a new position in Stryker Corporation (NYSE:SYK – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,839 shares of the medical technology company’s stock, valued at approximately $1,349,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sankala Group LLC acquired a new position in Stryker in the fourth quarter worth approximately $26,000. Tobam raised its position in Stryker by 4,504.0% during the fourth quarter. Tobam now owns 2,302 shares of the medical technology company’s stock valued at $809,000 after acquiring an additional 2,252 shares in the last quarter. Arwa LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $1,333,000. BDFS Capital LLC bought a new stake in Stryker in the fourth quarter worth approximately $522,000. Finally, Banque Transatlantique SA grew its position in Stryker by 10.3% in the fourth quarter. Banque Transatlantique SA now owns 176,367 shares of the medical technology company’s stock worth $62,048,000 after acquiring an additional 16,431 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on SYK. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research report on Friday, May 1st. Wells Fargo & Company decreased their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. cut their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, Truist Financial restated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Read Our Latest Research Report on Stryker

Stryker Stock Performance

NYSE SYK opened at $308.62 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a market capitalization of $118.31 billion, a price-to-earnings ratio of 35.72, a P/E/G ratio of 1.97 and a beta of 0.78. The company’s fifty day moving average is $313.81 and its two-hundred day moving average is $341.71. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.